Quick Facts: Uses and Indications

• Pregnancy Support: Used to help manage threatened and recurrent miscarriage.
• Uterine Health: May be used to address threatened premature labor.
• Obstetrics: Sometimes used as a component of care for intrauterine growth restriction (IUGR).

Allylestrenol is a medication that may be prescribed by a healthcare provider primarily in obstetrics and gynecology. Its main applications relate to supporting pregnancy in individuals who may be at an elevated risk of specific complications.

Allylestrenol is used to manage the risk of threatened abortion and recurrent miscarriage, and it may contribute to a more stable uterine environment for the continuation of pregnancy. Its use may also be associated with addressing threatened premature labor in some patients. In addition, Allylestrenol has been investigated for potential use in managing intrauterine growth restriction (IUGR).

The medication has been widely utilized in various countries globally for these indications.

Eligibility Profile: Who Can and Cannot Use Allylestrenol?

This section outlines the official eligibility and non-eligibility requirements for Allylestrenol, based strictly on government regulatory documents.

Allylestrenol is absolutely contraindicated (must not be used) in patients with the following conditions:

• Hypersensitivity or allergy to Allylestrenol or any component of the formulation.
• Known or suspected hormone-dependent malignancies (cancers).
• Severe liver disease, including specific conditions like Cholestatic Jaundice, Hepatitis, and Hepatic Cell Tumours.
• Undiagnosed abnormal vaginal bleeding.
• Incomplete Abortion or Toxaemia of Pregnancy.

Restrictions and Conditional Use

Use of Allylestrenol requires special consideration and caution in patients with a history of:

• Thromboembolic disorders (blood clots) or cardiovascular disease.
• Kidney disease or renal dysfunction.
• Seizures (Epilepsy) or migraine headaches.
• Depression or asthma.

Age and Life Stage Eligibility

• Pediatric Use: The medicine is not recommended for children under 16 years old, as its safety and effectiveness have not been established in this age group.
• Pregnancy: Allylestrenol is one of the few hormonal agents specifically intended for use during pregnancy to address certain complications, which defines its primary eligibility.
• Breastfeeding: Use is not recommended while breastfeeding.

Allylestrenol Interactions with other medicines and products

The official regulatory profile for Allylestrenol is fundamentally defined by its restricted availability in major international markets. Allylestrenol is not currently approved for use or widely marketed in the United States or Canada, which means that comprehensive drug-drug interaction information is not publicly available in accessible regulatory prescribing documents from authorities such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA).

As a result, the accessible official regulatory information does not formally classify or detail specific interaction constraints across several crucial categories:

Interaction Domain	Official Regulatory Status (Accessible Sources)
Contraindicated Combinations	None formally classified.
Metabolic Interactions (PK)	No specific CYP enzyme or transporter-based interactions are listed.
Exposure Modification	No substances are officially listed as raising or lowering drug levels.
Timing Rules	No mandatory separation of administration times is documented.
Food, Alcohol, Supplements	No specific interactions are cited in the accessible official labels.

This documentation status defines the product's official interaction structure. The regulatory statements do not identify specific substances as posing a clinically significant interaction risk, nor do they impose usage constraints such as mandatory timing requirements. The overall interaction profile reflects an absence of explicit prohibitions or procedural constraints in accessible government data.

Allylestrenol is a synthetic progestogen that primarily acts as an agonist for the Progesterone Receptors (PRs), modulating physiological processes related to myometrial and immune function.

Receptor Agonism and Uterine Quiescence

This mechanistic domain focuses on Allylestrenol's direct binding to Progesterone Receptors (PRs) in the myometrium (uterine muscle). This action influences cellular dynamics within the uterine tissue, dampening the excitability of the muscle and reducing the expression of contraction-inducing molecules like oxytocin receptors and prostaglandins, leading to uterine quiescence.

Immunomodulation at the Fetomaternal Interface

The drug's progestogenic signaling influences the local immune system at the implantation site. It shifts maternal immune activity from a pro-inflammatory T helper 1 (Th1) profile toward a T helper 2 (Th2) profile, a shift that influences maternal immune response at the fetomaternal interface, affecting immune cell activity.

Endometrial Regulation and Decidual Stability

Allylestrenol engages in hormonal regulation influencing the structural characteristics of the uterine lining. This mechanism promotes proper decidualization and maintains the necessary vascularization and stability of the endometrium, which contributes to the structural characteristics of the placental foundation.

Allylestrenol is a synthetic progestogen typically available as an oral tablet, primarily prescribed to help maintain pregnancy in cases of threatened or recurrent miscarriage and to prevent premature labor. You must take this medication exactly as directed by your healthcare professional.

General Administration

• Oral Use: Swallow the tablet whole with water. Do not crush or chew it.
• With or Without Food: Allylestrenol can be taken with or without food, but taking it consistently—either always with food or always without—may aid in better absorption and efficacy.
• Consistency: Take your dose at the same time each day to help maintain steady drug levels in your body.

Dosage and Duration

Your healthcare provider will determine the dosage and duration of treatment based on your specific medical condition and indication. Common dosing regimens vary significantly, for example:

• Threatened Abortion/Miscarriage: A suggested regimen is often 5 mg three times daily for approximately five to seven days, which may be extended as needed.
• Habitual (Recurrent) Abortion: Treatment may start with 5 mg daily after pregnancy confirmation and may continue until at least one month after the period of risk has passed.

Do not stop taking Allylestrenol abruptly, even if your symptoms improve, without consulting your doctor. A gradual reduction in dosage may be necessary to avoid hormonal imbalance. Report any unusual side effects or worsening conditions to your physician immediately.

---

Indication (Examples)	Suggested Dosing Regimen
Threatened Abortion	5 mg three times daily for 5-7 days
Habitual Abortion	5 mg daily, continued as per medical advice

---

Note: Dosage is highly individualized. Only follow the specific regimen prescribed by your healthcare provider, as the doses listed above are for informational context only.

Allylestrenol: Recent Clinical Evidence

This section provides a summary of the clinical research and evidence patterns related to Allylestrenol, drawing from authoritative studies and regulatory overviews. It describes the types of research that have been conducted, the areas they have explored, and where research remains limited or uncertain.

---

Evidence for Use in Recurrent Miscarriage and Threatened Abortion

Research has explored the role of Allylestrenol in contexts associated with maintaining pregnancy. For recurrent miscarriage (defined as two or more prior pregnancy losses), studies have primarily relied on randomized controlled trials (RCTs) and comparative clinical studies, focusing on pregnant women with this history. Research examined measured outcomes, including key pregnancy metrics such as live birth rates after 24 weeks and the rates of pregnancy loss before the second trimester.

For threatened abortion, evidence was largely derived from comparative clinical studies, including observational designs. These studies observed pregnant women who were experiencing signs indicative of threatened loss. Research examined delivery outcomes, monitoring successful delivery rates and overall miscarriage rates. Data for certain specialized groups, such as those with comorbid conditions, remain insufficient. Evidence is limited due to a smaller number of dedicated, large-scale RCTs in this acute setting.

---

Research Structure for Fertility Support (Luteal Phase)

Allylestrenol was evaluated in research exploring its use for luteal phase support in women undergoing Assisted Reproductive Techniques (ART), such as in vitro fertilization (IVF). The evidence base mainly relies on large-scale retrospective observational studies. These studies explored fertility metrics, and the outcomes measured included the clinical pregnancy rate and the live birth rate. Findings describe patterns observed in the studies where pregnancy rates were documented alongside those of other established therapies used for luteal support. Research exploring its use in ART has limitations because the studies were retrospective.

---

Long-Term Evidence and Research Gaps

Research for Allylestrenol was focused on outcomes measured over short-term and intermediate periods of pregnancy, generally spanning the first and second trimesters and extending through the delivery date. While research reports how pregnancy outcomes evolved in the observed populations up to the point of birth, there is limited information for long-term outcomes or durability of effect beyond the immediate postnatal period.

Key limitations include the fact that sample sizes were modest in some of the most relevant older studies. There is a paucity of dedicated, high-quality, contemporary research specifically focused on secondary uses, such as threatened premature labor and Intrauterine Growth Restriction (IUGR). Continued research is ongoing to fill these existing evidence gaps.

Allylestrenol tablets must be stored according to the requirements specified in the official labeling to maintain their effectiveness and stability.

Storage Conditions

Scope Element	Official Regulatory Requirement
Temperature	Store below 30 C (room temperature). Do not freeze or refrigerate.
Protection	Must be protected from light and moisture.
Packaging	Keep the tablets in the original outer carton/packaging until use.
Child-Safety	Keep out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Disposal of unused or expired Allylestrenol must comply with local waste management protocols. Unused medicine should be disposed of in accordance with local requirements for drug waste, such as official take-back programs. Medicines must not be thrown away via wastewater (flushing down the toilet) to prevent environmental contamination.